Ultragenyx, after setbacks, nabs first gene therapy approval
BioPharma Dive
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.
pharminent
August 20, 2026 (Last updated: September 1, 2026)
BioPharma Dive
The clearance of Genglycos for a rare glycogen storage disease gives Ultragenyx a sellable voucher and momentum ahead of an eagerly anticipated study readout.